EE266 Societal Economic Impact of Treatment with Adjuvant Osimertinib in Patients with Early-Stage (IB-IIIA) EGFRm NSCLC
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.567
https://www.valueinhealthjournal.com/article/S1098-3015(23)00667-8/fulltext
Title :
EE266 Societal Economic Impact of Treatment with Adjuvant Osimertinib in Patients with Early-Stage (IB-IIIA) EGFRm NSCLC
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00667-8&doi=10.1016/j.jval.2023.03.567
First page :
Section Title :
Open access? :
No
Section Order :
10048